Document Detail

Hemodynamic effects during rest and exercise of bucindolol in hypertensive men.
MedLine Citation:
PMID:  2890669     Owner:  NLM     Status:  MEDLINE    
Bucindolol is an investigational beta-adrenergic blocking agent with intrinsic sympathomimetic and vasodilatory activity in animals. In a double-blind, six-way, crossover study of six mild-to-moderate hypertensive men, the effects of bucindolol 100, 200, and 300 mg/d on resting blood pressure, heart rate, forearm blood flow, and vascular resistance measured by pneumoplethysmography, and blood pressure and heart rate after cycle and handgrip exercise were compared with those of propranolol 160 and 320 mg/d and placebo after q12h administration for five doses. Both bucindolol and propranolol significantly suppressed heart rate after cycle exercise in comparison with placebo (-33 to -48 beats/min), demonstrating beta blockade. Suppression of resting heart rate by propranolol (-20 beats/min) was significantly (P less than .05) greater than bucindolol (-7 to -8 beats/min); a similar treatment difference in heart rate was noted after handgrip exercise (-18 to -19 vs -1 to -8 beats/min, respectively). Bucindolol and propranolol decreased resting blood pressure to the same extent (in comparison with placebo; P less than .05 at peak activity, 2 hr postdose). Bucindolol tended to increase forearm blood flow and decrease forearm vascular resistance (P less than .05 at 4 hr postdose) in comparison with placebo. The effect of propranolol on forearm blood flow and forearm vascular resistance was not significant compared with placebo. These data are consistent with intrinsic sympathomimetic and vasodilatory activity of bucindolol in hypertensive men.
D P Conner; P H Vlasses; R A Clementi; A Oren; D Deitchman; R K Ferguson
Related Documents :
8610899 - The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats.
8436159 - Differential effects of beta-adrenoceptor partial agonists in patients with postural hy...
22801699 - Review: ace-is or arbs reduce adverse cv outcomes regardless of baseline systolic blood...
3709639 - Acute and long-term haemodynamic effects of propranolol and indenolol in hypertension.
6132819 - Ventilatory and haemodynamic effects of prenalterol and terbutaline in asthmatic patients.
10949 - Pharmacological effects of labetalol in man.
20078079 - Antihypertensive effect of benifuuki tea containing o-methylated egcg.
21456219 - Consolidation of binderless nanostructured tic by pulsed current activated sintering an...
1602279 - Dimensional analysis of the ventricle of an in situ perfused trout heart using echocard...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  27     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  1987 Apr 
Date Detail:
Created Date:  1988-01-11     Completed Date:  1988-01-11     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  300-3     Citation Subset:  IM    
Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology*,  therapeutic use
Clinical Trials as Topic
Double-Blind Method
Heart Rate / drug effects
Hemodynamics / drug effects*
Hypertension / drug therapy*,  physiopathology
Physical Exertion
Propanolamines / pharmacology*,  therapeutic use
Random Allocation
Regional Blood Flow / drug effects
Vascular Resistance / drug effects
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Propanolamines; 70369-47-0/bucindolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The influence of food on the oral absorption of bevantolol.
Next Document:  Respiratory effects of quazepam and pentobarbital.